Disclosed are an alkyl acrylate-aromatic vinyl compound-vinyl cyanide compound copolymer which is prepared using a polyalkylene cross-linking agent such as polyethylene glycol diacrylate or polyethylene glycol dimethacrylate for a core of the alkyl acrylate-aromatic vinyl compound-vinyl cyanide compound copolymer and thus advantageously improves low-temperature impact strength of resins when the copolymer is applied to a polycarbonate resin composition, and the polycarbonate resin composition comprising the copolymer.

Disclosed are an alkyl acrylate-aromatic vinyl compound-vinyl cyanide compound copolymer which is prepared using a polyalkylene cross-linking agent such as polyethylene glycol diacrylate or polyethylene glycol dimethacrylate for a core of the alkyl acrylate-aromatic vinyl compound-vinyl cyanide compound copolymer and thus advantageously improves low-temperature impact strength of resins when the copolymer is applied to a polycarbonate resin composition, and the polycarbonate resin composition comprising the copolymer.

Disclosed are an alkyl acrylate-aromatic vinyl compound-vinyl cyanide compound copolymer which is prepared using a polyalkylene cross-linking agent such as polyethylene glycol diacrylate or polyethylene glycol dimethacrylate for a core of the alkyl acrylate-aromatic vinyl compound-vinyl cyanide compound copolymer and thus advantageously improves low-temperature impact strength of resins when the copolymer is applied to a polycarbonate resin composition, and the polycarbonate resin composition comprising the copolymer.

There is provided a powder that comprises a multistage polymer that comprises (a) at least one soft polymer having glass transition temperature of 40° C. or lower, and (b) at least one hard polymer having glass transition temperature higher than 40° C., wherein the glass transition temperature of said hard polymer is at least 10° C. higher than the glass transition temperature of said soft polymer,
wherein the weight ratio of said hard polymer to said soft polymer is from 1.01:1 to 100:1, and
wherein said multistage polymer, after exposure to liquid water followed by drying at temperatures below 100° C., shows maximum thermal transition temperature in an atmosphere of 0% relative humidity that differs by 20° C. or less from the maximum thermal transition temperature in an atmosphere of 75% relative humidity.

There is provided a powder that comprises a multistage polymer that comprises (a) at least one soft polymer having glass transition temperature of 40° C. or lower, and (b) at least one hard polymer having glass transition temperature higher than 40° C., wherein the glass transition temperature of said hard polymer is at least 10° C. higher than the glass transition temperature of said soft polymer,
wherein the weight ratio of said hard polymer to said soft polymer is from 1.01:1 to 100:1, and
wherein said multistage polymer, after exposure to liquid water followed by drying at temperatures below 100° C., shows maximum thermal transition temperature in an atmosphere of 0% relative humidity that differs by 20° C. or less from the maximum thermal transition temperature in an atmosphere of 75% relative humidity.

The composition contains a compound represented by Formula 1, a binder polymer, a photopolymerization initiator, and a monomer having a carboxy group, in which the content of the compound represented by Formula 1 is 5% by mass or more and less than 50% by mass with respect to the total mass of monomer components, and in Formula 1, Q.sup.1 and Q.sup.2 each represent a (meth)acryloyloxy group, and R.sup.1 represents a divalent linking group having a chain-like structure.

Q.sup.2-R.sup.1-Q.sup.1  (1)

This invention relates to compositions and medical devices comprising anti-microbial active particles, for inhibiting microbial growth. This invention further provides methods of making such compositions and medical devices.

This invention relates to compositions and medical devices comprising anti-microbial active particles, for inhibiting microbial growth. This invention further provides methods of making such compositions and medical devices.

The current invention relates to a process for preparing an aqueous binder composition free of organic solvent, the process comprising at least the following steps: A) preparing a hydrophilic vinyl polymer (Polymer A) by polymerisation of a monomer composition A that contains: Ai) at least one carboxylic acid functional olefinically unsaturated monomer; and Aii) at least one olefinically unsaturated monomer different than Ai); and Aiii) optionally at least one wet adhesion promoting olefinically unsaturated monomer different than Ai and Aii); where Polymer A has an acid value (AV) from 32 to 98 mg KOH/g of solid Polymer A; B) preparing a hydrophobic vinyl polymer (Polymer B) by emulsion polymerization of a monomer composition B in the presence of Polymer A where the monomer composition B contains: Bi) at least one olefinically unsaturated monomer; Bii) optionally carboxylic acid functional olefinically unsaturated monomer different than Bi); and Biii) optionally wet adhesion promoting olefinically unsaturated monomer different than Bi); where Polymer B has an acid value (AV) of no more than 23.4 mg KOH/g of solid polymer B, wherein at least a part of the carboxylic acid groups that are present in Polymer A and Polymer B are neutralized during or following the steps A and/or B to form a (partially) neutralized polymer emulsion; where the weight average molecular weight (Mw) of Polymer A is lower than the weight average molecular weight (Mw) of polymer B; and wherein the process is further characterized by the presence of a further step C) reacting at least 10 mol % of the carboxylic acid and/or carboxylate salt groups of the (partially) neutralized polymer emulsion with an iminating agent to produce an iminated polymer C; wherein the total amount of surfactant applied in steps A, B and C is at most 0.5 wt. %, based on the total weight of monomers charged for the preparation of polymer A and polymer B

Disclosed herein are compositions and methods for reducing the antigenicity of molecules. The antigenicity of a molecule may be reduced or eliminated by conjugating at least one branched polymer to the molecule to form a molecule-polymer conjugate. The branched polymer may include a backbone and a plurality of side chains, each side chain covalently attached to the backbone.